Table 2.
Clinical characteristics of patients upon study entry in relation to histidine-rich calcium genotype
| Ser/Ser (n = 31) | Ser/Ala (n = 61) | Ala/Ala (n = 31) | |
|---|---|---|---|
| Age at study entry, years | 42.5 ± 14.0 | 51.5 ± 11.8 | 48.9 ± 16.1 |
| Sex, male/female | 6 (19.4) | 13 (21.3) | 9 (29.0) |
| Clinical characteristics, n (%) | |||
| Familial DCM | 11 (35.5) | 24 (39.3) | 12 (38.7) |
| NYHA | |||
| Class I | 15 (48.4) | 27 (44.3) | 14 (45.2) |
| Class II | 13 (41.9) | 24 (39.3) | 14 (45.2) |
| Class III | 3 (9.7) | 10 (16.4) | 3 (9.7) |
| AF | 5 (16.1) | 9 (14.8) | 7 (22.6) |
| Left bundle branch block (LBBB) | 7 (22.6) | 23 (37.7) | 10 (32.3) |
| LVEF (%) | 29.6 ± 10.4 | 27.2 ± 9.6 | 30.2 ± 8.5 |
| LVEDD (mm) | 63.0 ± 15.3 | 65.6 ± 17.5 | 65.5 ± 14.8 |
| LVESD (mm) | 52.0 ± 13.9 | 52.1 ± 18.2 | 52.7 ± 13.6 |
| ICD (history of sustained VT or VF), n (%) | 1 (3.2) | 13 (21.3) | 12 (38.7) |
| History of unexplained syncope, n (%) | 4 (12.9) | 2 (3.3) | 2 (6.5) |
| Medication usage at enrolment, n (%) | |||
| ACE inhibitor | 27 (87.1) | 55 (90.2) | 25 (80.6) |
| Digitalis | 7 (22.6) | 19 (31.1) | 9 (29.0) |
| Spirinolactone | 15 (48.4) | 20 (32.8) | 12 (38.7) |
| Beta blockers | 23 (74.2) | 43 (70.5) | 27 (87.1) |
| Amiodarone | 15 (48.4) | 30 (49.2) | 12 (38.7) |
All values are mean ± standard deviation.
NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension; ICD, implantable cardioverter-defibrillator; VT, ventricular tachycardia; VF, ventricular fibrillation; ACE, angiotensin-converting enzyme.